Please login to the form below

Not currently logged in
Email:
Password:

Axovant

This page shows the latest Axovant news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Axovant Sciences dropped its 5-HT6 receptor antagonist intepirdine.

Latest news

  • After Axovant shock, Roivant pens diabetes deal with Poxel After Axovant shock, Roivant pens diabetes deal with Poxel

    After Axovant shock, Roivant pens diabetes deal with Poxel. Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal. ... Hung’s resignation hasn’t come out of the blue, given Axovant’s 5-HT6 receptor antagonist intepirdine has

  • Axovant joins ever-growing Alzheimer’s failure club Axovant joins ever-growing Alzheimer’s failure club

    Axovant joins ever-growing Alzheimer’ s failure club. 5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine. ... Axovant’s phase III trial of Alzheimer’s disease (AD) candidate intepirdine has ended in failure, an outcome

  • Roivant gets $1.1bn investment from Japan's SoftBank Roivant gets $1.1bn investment from Japan's SoftBank

    Roivant - the holding company for subsidiaries Axovant, Myovant, Dermavant, Enzyvant and just-launched urology specialist Urovant - said the cash injection will be used to launch new subsidiaries "within and beyond the ... Axovant for example is

  • Lundbeck trial failure dashes hopes in Alzheimer's once again Lundbeck trial failure dashes hopes in Alzheimer's once again

    Idalopirdine is being developed in partnership with Japanese drugmaker Otsuka. The news wreaked havoc on the shares of Axovant, another company developing a 5-HT6 inhibitor for Alzheimer's. ... Axovant's intepirdine candidate - licensed from

  • Soaring sales of Pfizer's Prevnar lead to calls for price cut Soaring sales of Pfizer's Prevnar lead to calls for price cut

    this class for AD - including Axovant which is developing a candidate formerly abandoned by GlaxoSmithKline (GSK). ... Shares in Axovant fell 25% yesterday on the news as investors got the jitters about RVT-105, its lead candidate that was recently

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Former GSK exec joins PureTech Health Former GSK exec joins PureTech Health

    Dr Pande currently serves on the board of directors for Karuna Pharmaceuticals - part of PureTech Health - as well as Axovant Sciences, Autifony Therapeutics, and Cennerv Pharma's scientific advisory board.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics